These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Wang C; McKeithan TW; Gong Q; Zhang W; Bouska A; Rosenwald A; Gascoyne RD; Wu X; Wang J; Muhammad Z; Jiang B; Rohr J; Cannon A; Steidl C; Fu K; Li Y; Hung S; Weisenburger DD; Greiner TC; Smith L; Ott G; Rogan EG; Staudt LM; Vose J; Iqbal J; Chan WC Blood; 2015 Oct; 126(15):1741-52. PubMed ID: 26268241 [TBL] [Abstract][Full Text] [Related]
65. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients. Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904 [TBL] [Abstract][Full Text] [Related]
66. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004 [TBL] [Abstract][Full Text] [Related]
67. Tall cell carcinoma with reversed polarity: A case report of a very rare breast tumor entity and mini-review. Trihia HJ; Lampropoulos P; Karelis L; Souka E; Galanopoulos G; Provatas I Breast J; 2021 Apr; 27(4):369-376. PubMed ID: 33527653 [TBL] [Abstract][Full Text] [Related]
68. [Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations]. Tong HY; Hu C; Yu MX; Ma QL; Chen FF; Ye L; Wei JY; Xu GX; Mao LP; Li Y; Jin J Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3180-4. PubMed ID: 24405536 [TBL] [Abstract][Full Text] [Related]
69. Mutant metabolic enzymes are at the origin of gliomas. Yan H; Bigner DD; Velculescu V; Parsons DW Cancer Res; 2009 Dec; 69(24):9157-9. PubMed ID: 19996293 [TBL] [Abstract][Full Text] [Related]
70. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455 [TBL] [Abstract][Full Text] [Related]
71. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. Horbinski C; Kofler J; Kelly LM; Murdoch GH; Nikiforova MN J Neuropathol Exp Neurol; 2009 Dec; 68(12):1319-25. PubMed ID: 19915484 [TBL] [Abstract][Full Text] [Related]
72. R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations. Kurek KC; Pansuriya TC; van Ruler MA; van den Akker B; Luks VL; Verbeke SL; Kozakewich HP; Sciot R; Lev D; Lazar AJ; Fletcher CD; Bovée JV Am J Pathol; 2013 May; 182(5):1494-500. PubMed ID: 23485734 [TBL] [Abstract][Full Text] [Related]
73. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337 [TBL] [Abstract][Full Text] [Related]
74. IDH mutations in glioma and acute myeloid leukemia. Dang L; Jin S; Su SM Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206 [TBL] [Abstract][Full Text] [Related]
75. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357 [TBL] [Abstract][Full Text] [Related]
76. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. Largeaud L; Bérard E; Bertoli S; Dufrechou S; Prade N; Gadaud N; Tavitian S; Bories P; Luquet I; Sarry A; De Mas V; Huguet F; Delabesse E; Récher C Leuk Res; 2019 Jun; 81():82-87. PubMed ID: 31055247 [TBL] [Abstract][Full Text] [Related]
77. Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples. Avsar T; Sursal A; Turan G; Yigit BN; Altunsu D; Cantasir K; Duyu G; Bayoumi AB; Yapicier O; Acar M; Kilic T Mol Diagn Ther; 2020 Jun; 24(3):327-338. PubMed ID: 32274701 [TBL] [Abstract][Full Text] [Related]
78. Breast Tumor Resembling Tall Cell Variant of Papillary Thyroid Carcinoma: A Solid Papillary Neoplasm With Characteristic Immunohistochemical Profile and Few Recurrent Mutations. Bhargava R; Florea AV; Pelmus M; Jones MW; Bonaventura M; Wald A; Nikiforova M Am J Clin Pathol; 2017 Apr; 147(4):399-410. PubMed ID: 28375433 [TBL] [Abstract][Full Text] [Related]
79. Clinicopathologic Features and Prognosis of Olfactory Neuroblastoma with Isocitrate Dehydrogenase 2 Mutations. Wu L; An J; Liu H World Neurosurg; 2022 Mar; 159():e23-e31. PubMed ID: 34856401 [TBL] [Abstract][Full Text] [Related]
80. Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients. Grassi S; Guerrini F; Ciabatti E; Puccetti R; Salehzadeh S; Metelli MR; Di Vita A; Domenichini C; Caracciolo F; Orciuolo E; Pelosini M; Mazzantini E; Rossi P; Mazziotta F; Petrini M; Galimberti S Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]